ETR:MOR - MorphoSys Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
€98.80 +0.10 (+0.10 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close€98.80
Today's Range€97.90 - €100.30
52-Week Range€49.63 - €88.10
Volume113,622 shs
Average Volume153,687 shs
Market Capitalization$2.49 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MorphoSys logoMorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company's product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao. The company was founded in 1992 and is headquartered in Planegg, Germany.

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange ETR
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolETR:MOR
CUSIPN/A
Phone+49-89-899270

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-159.62%
Return on Equity-25.28%
Return on Assets-22.11%

Miscellaneous

EmployeesN/A
Outstanding Shares29,010,000
Market Cap$2.49 billion

MorphoSys (ETR:MOR) Frequently Asked Questions

What is MorphoSys' stock symbol?

MorphoSys trades on the ETR under the ticker symbol "MOR."

What price target have analysts set for MOR?

10 equities research analysts have issued 12 month price objectives for MorphoSys' shares. Their forecasts range from €56.00 to €120.00. On average, they anticipate MorphoSys' share price to reach €94.60 in the next twelve months. This suggests that the stock has a possible downside of 4.3%. View Analyst Price Targets for MorphoSys.

What is the consensus analysts' recommendation for MorphoSys?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 2 sell ratings, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MorphoSys.

Who are some of MorphoSys' key competitors?

Who are MorphoSys' key executives?

MorphoSys' management team includes the folowing people:
  • Dr. Simon E. Moroney, Chairman of Management Board & CEO (Age 59)
  • Mr. Jens H. Holstein, CFO & Member of Management Board (Age 54)
  • Dr. Markus Enzelberger, Chief Scientific Officer & Member of Management Board (Age 48)
  • Dr. Malte Peters, Chief Devel. Officer & Member of Management Board (Age 56)
  • Dr. Marlies Sproll, Special Adviser to the Chief Exec. Officer (Age 60)

Has MorphoSys been receiving favorable news coverage?

Headlines about MOR stock have been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. MorphoSys earned a coverage optimism score of 0.17 on Accern's scale. They also gave media coverage about the company an impact score of 44.63 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for MorphoSys.

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately €98.80.

How big of a company is MorphoSys?

MorphoSys has a market capitalization of $2.49 billion.

How can I contact MorphoSys?

MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.


MarketBeat Community Rating for MorphoSys (ETR MOR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  301
MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote "Outperform" if you believe MOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.